The American Journal of Gastroenterology· 2014Q1· Derleme
Probiyotikler IBS ve KİB İçin Etkinlik Gösterdi, Ancak Spesifikler Belirsizliğini Koruyor
Efficacy of Prebiotics, Probiotics, and Synbiotics in Irritable Bowel Syndrome and Chronic Idiopathic Constipation: Systematic Review and Meta-analysis
- 742atıf
- Q1SCImago
- 2014yıl
Kısa özet
Probiyotikler, plaseboya kıyasla IBS semptomlarının devam etme olasılığını anlamlı şekilde azalttı (RR 0.79) ve global IBS, karın ağrısı, şişkinlik ve gaz skorlarını iyileştirdi.
Yapay zekâ ile başlık ve abstract'tan üretildi; tam metin okunmaz.
Ana noktalar
- Probiyotikler, plaseboya kıyasla IBS semptomlarının devam etme göreceli riskini %21 (RR 0.79) azalttı.
- Probiyotikler global IBS semptom skorlarını, karın ağrısını, şişkinliği ve gazı iyileştirdi.
- Probiyotikler Kronik İdiyopatik Kabızlık (KİB) hastalarında haftalık dışkı sayısını 1.49 artırdı (n=2 RKÇ).
- IBS ve KİB'de prebiyotikler ve sinbiyotikler için kanıtlar yetersiz veya belirsizdi.
Yapay zekâ ile başlık ve abstract'tan üretildi; tam metin okunmaz.
Özet (abstract)
OBJECTIVES: Irritable bowel syndrome (IBS) and chronic idiopathic constipation (CIC) are functional bowel disorders. Evidence suggests that disturbance in the gastrointestinal microbiota may be implicated in both conditions. We performed a systematic review and meta-analysis to examine the efficacy of prebiotics, probiotics, and synbiotics in IBS and CIC. METHODS: MEDLINE, EMBASE, and the Cochrane Controlled Trials Register were searched (up to December 2013). Randomized controlled trials (RCTs) recruiting adults with IBS or CIC, which compared prebiotics, probiotics, or synbiotics with placebo or no therapy, were eligible. Dichotomous symptom data were pooled to obtain a relative risk (RR) of remaining symptomatic after therapy, with a 95% confidence interval (CI). Continuous data were pooled using a standardized or weighted mean difference with a 95% CI. RESULTS: The search strategy identified 3,216 citations. Forty-three RCTs were eligible for inclusion. The RR of IBS symptoms persisting with probiotics vs. placebo was 0.79 (95% CI 0.70-0.89). Probiotics had beneficial effects on global IBS, abdominal pain, bloating, and flatulence scores. Data for prebiotics and synbiotics in IBS were sparse. Probiotics appeared to have beneficial effects in CIC (mean increase in number of stools per week=1.49; 95% CI=1.02-1.96), but there were only two RCTs. Synbiotics also appeared beneficial (RR of failure to respond to therapy=0.78; 95% CI 0.67-0.92). Again, trials for prebiotics were few in number, and no definite conclusions could be drawn. CONCLUSIONS: Probiotics are effective treatments for IBS, although which individual species and strains are the most beneficial remains unclear. Further evidence is required before the role of prebiotics or synbiotics in IBS is known. The efficacy of all three therapies in CIC is also uncertain.
Yazarların özeti; kaynağından alınmıştır. The American Journal of Gastroenterology, 2014 · DOI ↗
Ücretsiz hesapla devam et
Makaleye Sor ile bu makaleye günde 3 soru ücretsiz; makaleyi kaydet, kaynakçasını al, ilgi alanına göre her gün yeni özetler. Çıkarımlar Premium.
Web'de ücretsiz devam etGoogle ya da Apple hesabınla giriş; kart istemez. Bu makaleye geri dönersin.
Telefonda:
Alan: Gastroenteroloji
GastroenterologyMedicine